$SYK

Fletcher Robert S sold $861K of SYK

Fletcher Robert S (VP, Chief Legal Officer) sold 2,809 shares of STRYKER CORP (SYK) at $306.56 ($0.86M total) on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fletcher Robert S
Published May 29, 2026, 8:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SYK
Neutral
medium confidence
Mentioned
$SYK
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SYKNeutralLow
01

Why it matters

The disclosure provides a datapoint on insider activity but does not indicate a new fundamental catalyst; the 10b5-1 plan wording generally limits bearish interpretation.

02

Market read

Traders may monitor for follow-on insider activity, but the specified 10b5-1 plan makes the immediate trading signal weak.

03

What to watch

If multiple insiders sell around the same time (not shown here), the pattern could matter more than a single 10b5-1 sale.

Relevance 6/10Novelty 6/10Timing: Filed today; sale occurred on 2026-05-28.

Background

This is an SEC Form 4 insider transaction: a corporate officer reports a sale of the company’s shares.

Company-level read

Ticker impact

$SYKNeutralMedium confidence
Context

Stryker (SYK) is the issuer of an SEC Form 4 showing VP/Chief Legal Officer Fletcher Robert S sold 2,809 shares open-market under a 10b5-1 plan.

Expected impact

Likely minimal price impact; any effect should be short-lived and sentiment-driven.

Evidence & confidence

The filing is an ownership-change disclosure (not earnings/M&A/regulatory). The article specifies a Rule 10b5-1 pre-arranged plan, which reduces interpretive value versus discretionary selling.

Market effects

No clear sector read-through; this is company-specific insider transaction disclosure.

None.

None.

Counterpoint

Because the sale is pre-arranged under 10b5-1, it may reflect routine liquidity planning rather than bearish expectations; traders may ignore it.

Key entities

  • Stryker Corp

    SYK is the company whose shares were sold by an officer under a Rule 10b5-1 plan.

  • Fletcher Robert S

    VP, Chief Legal Officer; sold 2,809 shares at $306.5640 on 2026-05-28.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SYKHighAI 8/10

Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS

Stryker (SYK) shares fell $26.70 (-8.8%) on Sept. 8, 2026, after its CFO revealed persisting manufacturing issues in its Peripheral Vascular unit, acquired from Inari Medical. The firm Hagens Berman is investigating potential disclosure violations. The issue, initially thought resolved, led to lost sales and backorders, with the CFO stating it will continue into Q4.

$SYKLow

Why Stryker (SYK) Stock Is Down Today

Stryker (SYK) shares fell 6.9% after management at a healthcare conference indicated longer-than-expected supply chain issues and slower joint replacement recovery, potentially affecting revenue. The company had reported solid Q2 results in July. Insider sales and mixed hedge fund activity were also noted.

$SYKMed

Stryker stock drops 7.7% as supply problems and weak joint replacement sales hit outlook

Stryker shares dropped 7.7% on Tuesday due to ongoing supply chain issues and weaker-than-expected joint replacement sales. CFO Preston Wells stated that manufacturing problems will persist into Q4, impacting sales growth. The company also missed recovery expectations in its joint replacement business, citing seasonal weakness. Investors are concerned about the timing of a broader recovery.